

PREFERABLE-EFFECT study: mean and SD of all QLQ-C30 and -FA12 subscales at baseline, 3-, 6-, and 9-months

For meta-analysis purposes

Please cite: Hiensch, A.E., Depenbusch, J., Schmidt, M.E. et al. Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial. *Nat Med* 30, 2957–2966 (2024). <https://doi.org/10.1038/s41591-024-03143-y>

		Baseline EX=178, CG=179	3 months EX=157, CG=147	6 months EX=151, CG=134	9 months EX=142, CG=129
EORTC QLQ-C30					
Summary score	EX	74.1 (15.5)	77.8 (15.5)	78.6 (14.6)	78.6 (16.1)
	CG	74.6 (13.1)	75.4 (14.9)	75.4 (14.0)	75.2 (13.5)
Global QoL	EX	63.5 (17.3)	65.3 (20.0)	66.6 (19.3)	66.1 (21.8)
	CG	63.6 (18.2)	63.5 (18.4)	63.2 (19.6)	62.1 (16.9)
Physical functioning	EX	78.4 (16.8)	81.7 (17.6)	82.6 (16.6)	81.7 (18.5)
	CG	78.2 (16.4)	79.0 (18.2)	77.2 (19.4)	76.3 (18.6)
Emotional functioning	EX	65.0 (24.2)	69.2 (24.3)	71.0 (21.7)	71.0 (23.2)
	CG	64.8 (23.0)	70.5 (22.2)	70.9 (18.7)	70.4 (18.9)
Role functioning	EX	71.3 (27.4)	74.2 (28.1)	74.9 (27.3)	73.2 (28.9)
	CG	72.4 (24.9)	70.2 (27.5)	68.5 (25.8)	67.6 (26.6)
Social functioning	EX	68.3 (28.5)	74.3 (26.7)	74.1 (25.9)	78.4 (25.7)
	CG	66.5 (26.9)	70.9 (25.7)	69.5 (27.0)	69.0 (26.1)
Cognitive functioning	EX	72.4 (27.0)	78.2 (22.0)	77.9 (24.0)	78.2 (23.9)
	CG	74.1 (21.9)	76.4 (21.4)	76.6 (21.3)	77.3 (19.0)
Fatigue	EX	42.8 (25.8)	36.6 (25.3)	35.5 (23.9)	35.5 (27.2)
	CG	44.6 (23.6)	41.2 (22.8)	43.0 (24.0)	43.0 (22.0)
Pain	EX	31.1 (25.6)	28.1 (25.8)	27.6 (22.8)	27.5 (26.6)
	CG	31.7 (24.7)	32.9 (27.1)	34.0 (27.7)	33.9 (25.6)
Nausea and vomiting	EX	7.6 (14.3)	7.0 (13.0)	6.0 (12.1)	6.7 (14.7)
	CG	6.8 (12.7)	7.1 (12.3)	8.2 (14.4)	9.0 (17.9)
Dyspnea	EX	26.2 (26.7)	20.6 (24.9)	17.7 (24.0)	17.8 (24.0)
	CG	25.0 (26.6)	22.2 (25.4)	22.1 (24.8)	19.1 (24.2)
Insomnia	EX	40.4 (31.3)	34.0 (28.4)	32.9 (27.8)	34.3 (28.9)
	CG	35.6 (28.8)	36.7 (28.6)	33.8 (28.9)	36.2 (29.2)
Appetite loss	EX	14.8 (24.3)	13.2 (23.5)	10.6 (19.8)	11.3 (21.3)
	CG	12.8 (22.1)	13.6 (25.8)	13.2 (23.1)	13.4 (23.4)
Constipation	EX	15.0 (25.3)	12.1 (23.3)	14.3 (25.7)	13.4 (24.8)
	CG	15.5 (26.5)	17.0 (24.5)	14.2 (23.6)	13.7 (23.4)
Diarrhea	EX	14.7 (25.2)	14.6 (23.4)	14.3 (22.3)	14.3 (21.9)
	CG	14.0 (26.9)	16.1 (26.3)	13.9 (23.9)	15.2 (24.7)
Financial difficulties	EX	19.3 (28.9)	16.8 (26.0)	16.1 (28.0)	14.6 (23.3)
	CG	19.0 (27.6)	16.6 (25.7)	16.7 (26.7)	16.0 (22.9)
EORTC QLQ-FA12					
Physical fatigue	EX	39.3 (24.9)	33.2 (26.1)	33.3 (24.8)	32.9 (27.7)
	CG	41.2 (23.5)	36.2 (22.5)	38.7 (24.5)	39.5 (22.5)
Emotional fatigue	EX	27.5 (24.4)	25.2 (26.7)	23.4 (25.6)	24.8 (24.9)
	CG	28.6 (25.7)	22.8 (21.0)	26.3 (23.7)	26.1 (23.8)
Cognitive fatigue	EX	15.7 (21.2)	12.7 (19.3)	12.8 (17.5)	11.3 (17.8)
	CG	15.3 (19.7)	12.8 (17.7)	14.1 (18.4)	12.0 (15.6)
Interference with daily activities	EX	34.3 (26.6)	31.8 (30.0)	30.7 (29.4)	28.9 (29.0)
	CG	38.2 (27.2)	34.7 (27.6)	38.6 (29.7)	37.7 (27.1)
Social sequelae	EX	13.9 (25.0)	11.9 (23.0)	11.3 (20.7)	10.3 (20.7)
	CG	13.6 (22.5)	13.9 (23.7)	12.9 (22.0)	14.7 (23.5)

EX exercise group; **CG** control group

Note, that in our publication (Hiensch *et al.* *Nature Medicine*) we report model-based between-group differences taking all available data into account. In the current table, the mean values (\pm SD) of patients who filled in the questionnaire at a certain time point are provided.